DOCSLIB.ORG

FY 2015 Trans-NIH Plan for HIV-Related Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FY 2015 Trans-NIH Plan for HIV-Related Research FY 2015 National Institutes of Health TRANS-NIH PLAN FOR HIV-RELATED RESEARCH Prepared by the Office of AIDS Research Jack Whitescarver, Ph.D. NIH Associate Director for AIDS Research and Director, Office of AIDS Research Dedicated to the Memory of SPENCER COX 1968–2012 An AIDS pioneer, treatment activist, research advocate, and friend. Spencer brought a unique energy and commitment to help us build an AIDS research program that is responsive to the epidemic, based on the most promising science, and inclusive of the voices of the community. He advocated for the highest possible scientific standards for clinical trials to provide clear and useful information for the trial participants and for HIV-infected individuals who may benefit from the research in the future. His voice will be missed. FY 2015 Trans-NIH Plan for HIV-Related Research CONTENTS 1 Legislative Mandate INTRODUCTION 3 Overview 4 HIV/AIDS Pandemic 5 NIH AIDS Research Program 10 NIH Office of AIDS Research 11 Trans-NIH Strategic Plan 12 OAR Budget Development Process 13 Extraordinary Opportunities for FY 2015 19 Conclusion PRIORITY: Expanding Basic Discovery Research 21 Etiology and Pathogenesis PRIORITY: Reducing New Infections 30 Vaccines 45 Microbicides 52 Behavioral and Social Science 64 Treatment as Prevention PRIORITY: Improving Disease Outcomes for HIV-Infected Individuals 70 Drug Discovery, Development, and Treatment 87 Research Toward a Cure PRIORITY: Reducing HIV-Related Disparities 97 Racial and Ethnic Populations 105 Women and Girls 113 Research in International Settings 130 Training, Infrastructure, and Capacity Building PRIORITY: Translating Research From Bench to Bedside to Community 136 Natural History and Epidemiology 147 Information Dissemination APPENDICES 152 Planning Groups 183 NIH Institutes and Centers 184 List of Acronyms FY 2015 Trans-NIH Plan for HIV-Related Research Legislative Mandate Section 2353 of the Public Health Service Act requires that the Director of OAR shall: (1) establish a comprehensive plan for the conduct and support of all AIDS activities of the agencies of the NIH; (2) ensure that the Plan establishes priorities among the AIDS activities that such agencies are authorized to carry out; (3) ensure that the Plan establishes objectives regarding such activities; (4) ensure that all amounts appropriate for such activities are expended in accordance with the Plan; (5) review the Plan not less than annually, and revise the Plan as appropriate; and (6) ensure that the Plan serves as a broad, binding statement of policies regarding AIDS activities of the agencies, but does not remove the responsibility of the heads of the agencies for the approval of specific programs or projects, or for other details of the daily administration of such activities, in accordance with the Plan. The law also specifically requires that the Plan provide for basic research, applied research, research conducted by the NIH, research supported by the NIH, proposals developed pursuant to solicitations by the NIH and investigator-initiated proposals, and behavioral and social sciences research. In accordance with the law, the NIH Office of AIDS Research, a component of the NIH Office of the Director, has developed this document. FY 2015 Trans-NIH Plan for HIV-Related Research 1 FY 2015 Trans-NIH Plan for HIV-Related Research Introduction Overview HIV/AIDS Pandemic NIH AIDS Research Program NIH Office of AIDS Research Trans-NIH Strategic Plan OAR Budget Development Process Extraordinary Opportunities for FY 2015 Conclusion Overview In the three decades since AIDS was first reported, the National Institutes of Health (NIH) has been the global leader in research to understand, prevent, diagnose, and treat HIV and its many related conditions. Recent scientific advances resulting from NIH-funded research represent a turning point for AIDS research. New avenues for discovery have been identified, providing possibilities for the development of new strategies to prevent, treat, and potentially cure HIV. The NIH is leading global research efforts to capitalize on those advances, move science forward, and begin to turn the tide against this pandemic. NIH research has resulted in landmark advances that have led to: Co-discovery of HIV, the virus that causes AIDS; Demonstration of the first proof of concept for the feasibility of a microbicide gel capable of Development of the first blood test for the disease, preventing HIV transmission; which has allowed diagnosis of infection as well as ensured the safety of the blood supply; Demonstration that the use of therapy by infected individuals can dramatically reduce transmission The critical discovery of key targets to develop to an uninfected partner; antiretroviral therapy (ART) and multidrug regimens that have resulted in improved life Demonstration of the potential feasibility of expectancy for those with access to and who can pre-exposure prophylaxis (PrEP), that long-term tolerate these drugs; and the development of use of ART regimens by some groups of high-risk treatments for many HIV-associated coinfections, uninfected individuals can reduce risk of HIV comorbidities, malignancies, and clinical acquisition; manifestations, with benefits for patients also suffering from those other diseases; Discovery that genetic variants may play a role in protecting some individuals, known as “elite Groundbreaking strategies for the prevention of controllers,” who have been exposed to HIV over mother-to-child transmission, which have resulted an extended period, from developing symptoms in dramatic decreases in perinatal HIV in the and enabling them to control the infection United States and in low-income countries; without therapy; Demonstration that the use of medical male Critical basic science discoveries that continue to circumcision can reduce the risk of HIV acquisition; provide the foundation for novel research; and The first step inproving the concept that a vaccine Progress in both basic and treatment research to prevent HIV infection is feasible; and discovery efforts aimed at eliminating viral reservoirs in the of two potent human antibodies that can stop body, which is, for the first time, leading scientists more than 90 percent of known global HIV strains to design and conduct research aimed at a cure. from infecting human cells in the laboratory; NIH intramural and extramural researchers have produced two new exciting advances. NIH researchers published the results of studies utilizing potent human neutralizing antibodies that successfully suppressed a form of HIV in primates. This important research could potentially result in a new form of treatment for HIV that could be used as an adjunct to ART and could lead to opportunities for novel research to treat and potentially cure HIV. NIH-sponsored researchers also have made tremendous strides in producing and analyzing proteins that may provide an important new pathway in AIDS vaccine design. The NIH is leading global research efforts to capitalize on all of these advances, move science forward, and begin to turn the tide against this pandemic. FY 2015 Trans-NIH Plan for HIV-Related Research 3 HIV/AIDS Pandemic Despite this progress, the HIV/AIDS pandemic will remain the most serious global public health crisis of our time. The Joint United Nations Programme on HIV/AIDS (UNAIDS) reports that in 2013: More than 35 million people were estimated to be living with HIV/AIDS. About 2.1 million people became HIV-infected (about half of them women), or about 6,000 infected per day. 1.5 million people died of AIDS-related illnesses. In the United States, HIV/AIDS continues to be an unrelenting public health crisis, disproportionately affecting racial and ethnic populations, women of color, young adults, and men who have sex with men. The Centers for Disease Control and Prevention (CDC) estimates that: Approximately 1.1 million people are HIV-infected. Approximately 50,000 new infections occur each year. One in four people living with HIV infection in the United States is female. OFFICE OF THE DIRECTOR OFFICE OF AIDS RESEARCH National Institute Eunice Kennedy Shriver National Institute National Institute National Institute of Arthritis and National Cancer National Institute on Alcohol Abuse of Allergy and on Aging Musculoskeletal Institute of Child Health and and Alcoholism Infectious Diseases and Skin Diseases Human Development National Institute National Institute National Institute of National Institute on Deafness and National Institute on National Eye of Dental and Diabetes and Digestive of Environmental Other Communication Drug Abuse Institute Craniofacial Research and Kidney Diseases Health Sciences Disorders National Institute National Heart, National Human National Institute of National Institute National Institute of of General Medical Lung, and Blood Genome Research Neurological Disorders of Mental Health Nursing Research Sciences Institute Institute and Stroke National Center National Institute of Fogarty National Center National Institute on for Complementary National Library Biomedical Imaging International for Advancing Minority Health and and Alternative of Medicine and Bioengineering Center Translational Sciences Health Disparities Medicine Center for Center for NIH Clinical Information Scientific Center Technology Review FY 2015 Trans-NIH Plan for HIV-Related Research 4 NIH AIDS NIH AIDS RESEARCH PROGRAM Largest public investment in AIDS research Research Program in the world To address this pandemic, the NIH conducts and Encompasses
Load more

Recommended publications
  • Bacteriophages: Ecology and Applications Ramin Mazaheri Nezhad Fard 1,2*
    Iranian Journal of Virology 2018;12(2): 41-56 ©2018, Iranian Society of Virology Review Article Bacteriophages: Ecology and Applications Ramin Mazaheri Nezhad Fard 1,2* 1. Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 2. Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran Table of Contents Bacteriophages: Ecology and Applications………………………………………………....1 Abstract ...................................................................................................................................... 1 Introduction ................................................................................................................................ 2 Background ............................................................................................................................ 2 Ecology .................................................................................................................................. 2 Genomics ............................................................................................................................... 6 Collection ............................................................................................................................... 7 Applications ........................................................................................................................... 8 Conclusions .............................................................................................................................
    [Show full text]
  • Qualitative Study to Explore the Knowledge and Attitude of Pregnant Women Regarding HIV/AIDS Testing in Kotayk Region and in Yerevan, Armenia
    Qualitative study to explore the knowledge and attitude of pregnant women regarding HIV/AIDS testing in Kotayk region and in Yerevan, Armenia Utilizing Professional Publication Framework Henrik Khachatryan, MD, MPH candidate, American University of Armenia Primary Adviser: M. Thompson, MS, DrPH Secondary Adviser: K. White, RN, PhD, CNAA October 2005 Table of Contents INTRODUCTION ...........................................................................................................................................................1 Background Information and Literature review....................................................................................................1 Rationale for the Research and Research Questions.............................................................................................4 METHODS AND MATERIALS........................................................................................................................................5 Study design...........................................................................................................................................................5 Study population ....................................................................................................................................................5 Sampling and Study Setting...................................................................................................................................6 Data collection Instrument.....................................................................................................................................6
    [Show full text]
  • Partners with Mixed HIV Status
    Partners With Mixed HIV Status SERODISCORDANT RELATIONSHIPS Relationships in which one or more people has HIV and one or more people do not have HIV are sometimes called serodiscordant or mixed serostatus. The term serodiscordant is made up of two roots: 1. Sero—meaning blood 2. Discordant—meaning different or non-matching HIV isn’t the first topic that comes up when most people start dating. You may not know the HIV status of your partner(s). You might not even have been tested yourself. It can be very difficult to talk about HIV status. WHAT ARE THE SPECIAL ISSUES FOR SERODISCORDANT RELATIONSHIPS? People in mixed HIV status relationships face all the same things as other people in relationship. But there are some extra issues: The partner(s) with HIV might focus on not infecting their partner(s). The partner(s) who do not have HIV may concentrate on taking care of the person/people with HIV. This can cause a serious lack of balance in the relationship. HIV can cause changes in the body. Antiretroviral medications (ARVs) may have unpleasant side effects. This might give the partner(s) with HIV negative feelings about their body and their health. It may be difficult to feel attractive and have a normal romantic relationship. Fear of transmitting HIV can cause an excess of caution. This might even stop all sexual activity. Review the following fact sheets for more information: Stopping the Spread of HIV Safer Sex Guidelines Condoms Ways HIV is Transmitted Try to have open discussions about your desires, your fears, and your limits.
    [Show full text]
  • Evaluation of Methods for the Concentration and Extraction of Viruses from Sewage in the Context of Metagenomic Sequencing
    RESEARCH ARTICLE Evaluation of Methods for the Concentration and Extraction of Viruses from Sewage in the Context of Metagenomic Sequencing Mathis Hjort Hjelmsø1☯*, Maria HellmeÂr2☯, Xavier Fernandez-Cassi3, Natàlia Timoneda3,4, Oksana Lukjancenko1, Michael Seidel5, Dennis ElsaÈsser5, Frank M. Aarestrup1, Charlotta LoÈfstroÈ m2¤, SõÂlvia Bofill-Mas3, Josep F. Abril3,4, Rosina Girones3, Anna Charlotte Schultz2 a1111111111 1 Research Group for Genomic Epidemiology, The National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark, 2 Division of Microbiology and Production, The National Food Institute, a1111111111 Technical University of Denmark, Søborg, Denmark, 3 Laboratory of Virus Contaminants of Water and Food, a1111111111 Department of Genetics, Microbiology, and Statistics, University of Barcelona, Barcelona, Catalonia, Spain, a1111111111 4 Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, Catalonia, a1111111111 Spain, 5 Institute of Hydrochemistry, Chair of Analytical Chemistry, Technical University of Munich, Munich, Germany ☯ These authors contributed equally to this work. ¤ Current address: Food and Bioscience, SP Technical Research Institute of Sweden, Lund, Sweden * [email protected] OPEN ACCESS Citation: Hjelmsø MH, HellmeÂr M, Fernandez-Cassi X, Timoneda N, Lukjancenko O, Seidel M, et al. Abstract (2017) Evaluation of Methods for the Concentration and Extraction of Viruses from Viral sewage metagenomics is a novel field of study used for surveillance, epidemiological Sewage in the Context of Metagenomic Sequencing. PLoS ONE 12(1): e0170199. studies, and evaluation of waste water treatment efficiency. In raw sewage human waste doi:10.1371/journal.pone.0170199 is mixed with household, industrial and drainage water, and virus particles are, therefore, Editor: Patrick Tang, Sidra Medical and Research only found in low concentrations.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Guidelines, 2015
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory
    [Show full text]
  • Reticulate Evolution Everywhere
    Reticulate Evolution Everywhere Nathalie Gontier Abstract Reticulation is a recurring evolutionary pattern found in phylogenetic reconstructions of life. The pattern results from how species interact and evolve by mechanisms and processes including symbiosis; symbiogenesis; lateral gene transfer (that occurs via bacterial conjugation, transformation, transduction, Gene Transfer Agents, or the movements of transposons, retrotransposons, and other mobile genetic elements); hybridization or divergence with gene flow; and infec- tious heredity (induced either directly by bacteria, bacteriophages, viruses, pri- ons, protozoa and fungi, or via vectors that transmit these pathogens). Research on reticulate evolution today takes on inter- and transdisciplinary proportions and is able to unite distinct research fields ranging from microbiology and molecular genetics to evolutionary biology and the biomedical sciences. This chapter sum- marizes the main principles of the diverse reticulate evolutionary mechanisms and situates them into the chapters that make up this volume. Keywords Reticulate evolution · Symbiosis · Symbiogenesis · Lateral Gene Transfer · Infectious agents · Microbiome · Viriome · Virolution · Hybridization · Divergence with gene flow · Evolutionary patterns · Extended Synthesis 1 Reticulate Evolution: Patterns, Processes, Mechanisms According to the Online Etymology Dictionary (http://www.etymonline.com), the word reticulate is an adjective that stems from the Latin words “re¯ticulātus” (having a net-like pattern) and re¯ticulum (little net). When scholars identify the evolution of life as being “reticulated,” they first and foremost refer to a recurring evolutionary pattern. N. Gontier (*) AppEEL—Applied Evolutionary Epistemology Lab, University of Lisbon, Lisbon, Portugal e-mail: [email protected] © Springer International Publishing Switzerland 2015 1 N. Gontier (ed.), Reticulate Evolution, Interdisciplinary Evolution Research 3, DOI 10.1007/978-3-319-16345-1_1 2 N.
    [Show full text]
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By
    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
    [Show full text]
  • PRIMER Fall 2008 Volume 5 Issue 2
    the PRIMER Fall 2008 Volume 5 Issue 2 also in this issue Guts ’R Us?: CSP 2009 JGI News . 2 Genome of Simplest Animal Reveals Ancient User Community Faces: Lineage . 10 Selections Announced Alexandra Worden . 3 Using Metagenomics Super Bacteria for on Lake Washington Q: What do boat-boring the information that we gener- Super Alfalfa . 4 Microbes. 12 bivalves and stinkbirds have ate from these selections CSP2009 Project at in common? JGI Announcements . 16 promise to take us faster and Contaminated A: Their guts are just two of 44 further down the path toward Hanford Site . 6 new CSP 2009 targets. clean, renewable transporta- In the continuing effort to tion fuels while affording us a tap the vast, unexplored reaches more comprehensive under- Director Rubin of the Earth’s microbial and standing of the global carbon plant domains for bioenergy cycle,” says Eddy Rubin, DOE Reviews and environmental applications, JGI Director. “The range of the DOE JGI has announced its projects spans important ter- Genomics of latest portfolio of DNA sequenc- restrial contributors to bio- ing projects for the coming year. mass production in the Loblolly Biofuels in The 44 projects, culled from pine—the cornerstone of the Nature nearly 150 proposals received U.S. forest products industry— through the Community to phytoplankton, barely visible Genomics is accelerating Sequencing Program (CSP), will to the naked eye, but no less improvements for converting collectively generate more than important to the massive gen- plant biomass into biofuel, thus 60 billion nucleotides of data. eration of fixed carbon in our bringing closer to reality wide- “The scientific and techno- marine ecosystems.” spread use of an alternative to logical advances enabled by With new cont.
    [Show full text]
  • Use of Withdrawal (Coitus Interruptus) for Both Pregnancy and HIV Prevention Among Young Adults in Rakai, Uganda
    2421 Use of Withdrawal (Coitus Interruptus) for Both Pregnancy and HIV Prevention among Young Adults in Rakai, Uganda Jenny A. Higgins, PhD, MPH,* Laura Gregor, BS,* Sanyukta Mathur, DrPH, MS,† Neema Nakyanjo, MS,‡ Fred Nalugoda, MHS,‡ and John S. Santelli, MD, MPH† *University of Wisconsin, Madison, WI, USA; †Columbia University, New York, NY, USA; ‡Rakai Health Sciences Program, Kalisizo, Rakai District, Uganda DOI: 10.1111/jsm.12375 ABSTRACT Introduction. Although understudied in the context of AIDS, use of withdrawal (coitus interruptus) with or in place of other prevention methods affects exposure to both pregnancy and human immunodeficiency virus (HIV). Aim. We used mixed methods to assess use of withdrawal among 15–24-year-olds in a rural Ugandan setting with considerable HIV prevalence. Methods. We measured withdrawal reporting among (i) sexually active 15–24-year-olds enrolled in a quantitative community survey (n = 6,722) and (ii) in-depth qualitative interview participants systematically selected from the latest round of the community survey (N = 60). Respondents were asked about family planning and HIV prevention practices, including a direct question about withdrawal in the in-depth interviews. Main Outcome Measures. The main outcome measures were reports of current use of withdrawal on the quanti- tative survey (general question about family planning methods) and reports of current or recent use withdrawal in qualitative interviews (specific question about withdrawal). Qualitative interviews also probed for factors associated with withdrawal use. Results. Although less than 1% of quantitative survey participants spontaneously named withdrawal as their current family planning method, 48% of qualitative interview respondents reported current or lifetime use of withdrawal.
    [Show full text]
  • HIV and Pregnancy: a Short Review Sofoudis C* 2Nd Department of Obstetrics and Gynecology University of Athens, Aretaieion Hospital, Greece
    ical C lin as C e f R o l e Sofoudis, J Clin Case Rep 2014, 4:10 a p n o r r DOI: 10.4172/2165-7920.1000436 t u s o J Journal of Clinical Case Reports ISSN: 2165-7920 Case Report Open Access HIV and Pregnancy: A Short Review Sofoudis C* 2nd Department of Obstetrics and Gynecology University of Athens, Aretaieion Hospital, Greece Abstract The incidence and existence of human immunodeficiency virus concerning women of reproductive age continues to increase globally. The care of HIV-infected women is not simple and must be focused on including the current and future health of these women, the minimization of the risk of maternal–infant transmission and the maintenance of the well-being of the fetus and neonate. Many maternal and obstetrical factors can affect the vertical transmission. The answer to this problem is the optimal medical and obstetrical care. Keywords: Pregnancy; HIV; Vertical transmission of the correlation between its presence and the immunsupression [12,13]. There are many pathological connections which can clear Introduction out this correlation. To begin with, we must give a great attention to The human immunodeficiency virus continues to be expanded the compromised immune status and general poor health of HIV- around the world causing an estimated 16,000 new infections per day infected women which allow them to become more vulnerable to [1]. 2.1 million women and 590,000 children below age of 15 were infections and mostly to puerperal sepsis [14]. Additionally, HIV newly infected through their mothers before or during birth or through related thrombocytopenia may lead to increased risk of hemorrhage.
    [Show full text]
  • FAQ113 -- HIV and Pregnancy
    AQ The American College of Obstetricians and Gynecologists FREQUENTLY ASKED QUESTIONS FAQ113 fPREGNANCY HIV and Pregnancy • What is human immunodeficiency virus (HIV)? • How do you get HIV? • How do you get AIDS? • How long does it take for HIV to develop into AIDS? • Can HIV be treated? • If I am infected with HIV and pregnant, can I pass HIV to my baby? • What can I do to reduce the risk of passing HIV on to my baby? • Why is HIV treatment recommended during pregnancy? • Are there any side effects of HIV drugs? • What is my viral load? • Why is it important for my viral load and CD4 cell count to be monitored? • Should I still use condoms during sex even though I am pregnant? • Are there extra risks for me if I am HIV positive and I have a cesarean delivery? • After I give birth, how will I know if my baby is infected with HIV? • Glossary What is human immunodeficiency virus (HIV)? Human immunodeficiency virus (HIV) is the virus that causes acquired immunodeficiency syndrome (AIDS). How do you get HIV? HIV enters the bloodstream by way of body fluids, such as blood or semen. Once in the blood, the virus invades and kills CD4 cells. CD4 cells are key cells of the immune system. When these cells are destroyed, the body is less able to fight disease. How do you get AIDS? AIDS occurs when the number of CD4 cells decreases below a certain level and the person gets sick with diseases that the immune system would normally fight off.
    [Show full text]
  • British HIV Association Guidelines for the Management of HIV in Pregnancy and Postpartum 2018 (2019 Second Interim Update)
    British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2019 second interim update) BHIVA guidelines on the management of HIV in pregnancy and postpartum Guideline writing group Dr Yvonne Gilleece (Chair) Honorary Clinical Senior Lecturer and Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust Dr Shema Tariq Postdoctoral Clinical Research Fellow, University College London, and Honorary Consultant Physician in HIV, Central and North (Vice-chair) West London NHS Foundation Trust Ms Funmi Awosusi Barts Health NHS Trust, London/HIV Pharmacy Association Dr Alasdair Bamford Consultant in Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Foundation Trust, London Dr Sanjay Bhagani Consultant Physician in Infectious Diseases, Royal Free Hospital NHS Trust, London Dr Laura Byrne Locum Consultant in HIV Medicine, St George’s University Hospitals NHS Foundation Trust, London Dr Emily Clarke Consultant in Genitourinary Medicine, Royal Liverpool and Broadgreen University Hospitals NHS Trust Ms Polly Clayden UK Community Advisory Board representative/HIV treatment advocates network Dr Hermione Lyall Clinical Director for Children’s Services and Consultant Paediatrician in Infectious Diseases, Imperial College Healthcare NHS Trust, London Dr Rebecca Metcalfe Consultant in Sexual Health and HIV Medicine, NHS Greater Glasgow and Clyde Dr Adrian Palfreeman Consultant in Genitourinary Medicine, University Hospitals of Leicester NHS Trust
    [Show full text]